Tag - PRPO

Developments

Precipio launches HemeScreen AML

Precipio (NASDAQ:PRPO) launched its HemeScreen acute myeloid leukemia (AML) panel, which tests for the presence of mutations in certain genes to help develop a treatment plan for patients. The company noted that AML...

September 22, 2020

Developments

Precipio points to completed validation studies of IV-Cell and HemeScreen

Several large laboratories have successfully completed validation studies to test Precipio’s (NASDAQ:PRPO) IV-Cell cytogenetics media product, as well as its HemeScreen assay, and are proceeding towards placing orders...

September 26, 2019

Developments

Precipio and U of Penn in joint pathology diagnostics collaboration

Precipio (NASDAQ:PRPO) inked a new joint collaboration with the Department of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania to expand cancer patient access to...

September 5, 2019

Feature

Precipio aims to prevent misdiagnosis of blood-related cancers

Using a combination of advanced lab technologies, and a platform giving access to expert academic pathologists, Precipio (NASDAQ:PRPO) has staked out a unique position in its battle to prevent misdiagnosis of blood...

August 27, 2019

Developments

Precipio posts continuous improvement in Q2 pathology sales metrics

Precipio (NASDAQ:PRPO) reported results of three key performance metrics that together demonstrate the continued growth and positive impact of the expansion of its sales force in improving pathology sales performance...

August 13, 2019

Tag - PRPO

Precipio launches HemeScreen AML

Precipio points to completed validation studies of IV-Cell and HemeScreen

Precipio and U of Penn in joint pathology diagnostics collaboration

Precipio aims to prevent misdiagnosis of blood-related cancers

Precipio posts continuous improvement in Q2 pathology sales metrics

General

More